CannaPharmaRx is a small cannabis cultivator based in Alberta, Canada. The company operates a single 55,000 sq ft indoor grow facility in Cremona, Alberta, where it cultivates and processes dried cannabis flower — sold as dried flower and trim shake — targeting international medical cannabis markets, primarily Germany and Israel, rather than the domestic Canadian market. CannaPharmaRx received its Health Canada cultivation and processing licenses in late 2022 and began commercial production in 2023. The company sells dried flower on a per-gram basis, with pricing ranging from CAD $0.80/gram for lower-quality product in Canada and Portugal up to CAD $2.05/gram for premium, higher-THC flower in Germany and Israel. Revenue is driven by production volume multiplied by average selling price per gram. The company currently operates six of ten planned grow rooms, so production is well below the facility's potential. The primary near-term growth lever is expanding to all ten rooms and adding a second drying and packing room. Because CannaPharmaRx lacks EU Good Manufacturing Practices (EU-GMP) certification — required to ship directly to EU buyers — it routes all European product through a third-party intermediary for compliant packaging, adding cost and complexity. The company is pursuing EU-GMP certification to eventually remove this intermediary. A separate effort to build EU distribution via a CAD $4.5M stake in LTB Management was fully written off by year-end 2025. The company also faces a near-term financial risk: it is in default on royalty obligations owed to its primary lender, Koze Investments, whose security covers the entire operating subsidiary.